Learn More
OBJECTIVE To study retrospectively the response and side effects in two groups of patients with untreated multiple myeloma receiving bortezomib-based regimen (VD/VT) and vincristine combined with adriamycin and dexamethasone (VAD). METHODS Eighteen patients were enrolled in a group of VD or VT, receiving bortezomib 1.0 mg/m2 or 1.3 mg/m2 on days 1, 4, 8(More)
  • 1